Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1668

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 1668
---
 we do not have patent rights and then
use the information learned from such activities to develop competitive products for sale in our major commercial markets;

●any patents that we obtain, or are licensed to us, may not provide us with any competitive advantages
or protection against competitors, or may be challenged by third parties;

74

●we
                                            cannot predict the scope of protection of any patent issuing based on our patent applications,
                                            including whether the patent applications that we own or may in-license in the future will
                                            result in issued patents with claims that cover our product candidates or uses thereof in
                                            the United States or in other foreign countries;

●if
                                            we attempt to enforce our patents, a court may hold that our patents are not invalid, unenforceable
                                            or not infringed;

●we
                                            may not develop additional proprietary technologies that are patentable;

●we
                                            may need to initiate litigation or administrative proceedings to enforce and/or defend our
                                            patent rights which will be costly whether we win or lose;

●we
                                            may choose not to file a patent in order to maintain certain trade secrets or know-how, and
                                            a third party may subsequently file a patent covering such intellectual property;

●we
                                            may be required to change, redesign or stop using trademarks, service marks, domain names,
                                            logos, trade names and other identifiers that we own or use to avoid infringing the rights
                                            of third parties;

●we
                                            may fail to adequately protect and police our trade secrets; or

●the
                                            patents of others may have an adverse effect on our business, including if others obtain
                                            patents claiming subject matter similar to or improving that covered by our patents and patent
                                            applications.

Should any of these events
occur, they could significantly harm our business, results of operations and prospects.

Without patent protection
on the composition of matter of our product candidates, our ability to assert our patents to stop others from using or selling our product
candidates in a non-pharmaceutically acceptable formulation may be limited.

Due to the patent laws of
a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all
of our product candidates or methods involving these candidates in parent patent applications. We may have to pursue divisional patent
applications or continuation patent applications in the United States and other countries to obtain claim coverage for inventions which
were disclosed but not claimed in parent patent applications.

Moreover, it is